Brief: Nurexone Biologic Announces U.S. Uplisting Intention And Closes C$2.3 Million Private Placement
04/04/2025 14:17
April 4 (Reuters) - Nurexone Biologic Inc NRX.V: NUREXONE BIOLOGIC ANNOUNCES U.S. UPLISTING INTENTION AND CLOSES C$2.3 MILLION PRIVATE PLACEMENT Source text: ID:nGNXZ9m7b Further company coverage: NRX.V (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement